Advances in Anticancer Immunotoxin Therapy [PDF]
The Oncologist, 2015 Abstract Immunotoxins are a novel class of antibody-conjugated therapeutics currently in clinical development for a variety of malignancies. They consist of an antibody-based targeting domain fused to a bacterial toxin payload for cell killing.
Christine, Alewine +2 more
openaire +2 more sources
The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation
Biology, 2021 Type I Interferons (IFNs) are key regulators of natural and therapy-induced host defense against viral infection and cancer. Several years of remarkable progress in the field of oncoimmunology have revealed the dual nature of these cytokines. Hence, Type
Martina Musella +3 more
doaj +1 more source
Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs [PDF]
, 2009 This review illustrates notable recent progress in the field of medicinal bioinorganic chemistry as many new approaches to the design of innovative metal-based anticancer drugs are emerging.
Aird +75 more
core +1 more source
Bioactive peptides for anticancer therapies.
Biomaterials translational, 2023 Cancer is a serious concern in public health worldwide. Numerous modalities including surgery, radiotherapy, and chemotherapy, have been used for cancer therapies in clinic. Despite progress in anticancer therapies, the usage of these methods for cancer treatment is often related to deleterious side effects and multidrug resistance of conventional ...
Zhang, Yehao +3 more
openaire +2 more sources
Non-Coding RNAs: Foes or Friends for Targeting Tumor Microenvironment
Non-Coding RNA, 2023 Non-coding RNAs (ncRNAs) are a group of molecules critical for cell development and growth regulation. They are key regulators of important cellular pathways in the tumor microenvironment.
Anna Szymanowska +3 more
doaj +1 more source
A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship [PDF]
, 2007 We undertook a systematic review of the pre-clinical and clinical literature for studies investigating the relationship between platinum and taxane resistance.
Davey, Ross +2 more
core +1 more source
Pegylation – in search of balance and enhanced bioavailability
Journal of Medical Science, 2022 In the process of finding better therapeutics, thousands of new molecules are synthesised every day. Many of these can be poorly soluble in water, leading to a potentially promising drug being rejected during testing due to its poor solubility ...
Dawid Łażewski +2 more
doaj +1 more source
Biomedicines, 2021 Over the last decade, we have seen tremendous progress in research on 2-deoxy-D-glucose (2-DG) and its analogs. Clinical trials of 2-DG have demonstrated the challenges of using 2-DG as a monotherapy, due to its poor drug-like characteristics, leading ...
Beata Pająk +8 more
doaj +1 more source
Future of 5-fluorouracil in cancer therapeutics, current pharmacokinetics issues and a way forward [PDF]
, 2019 Background: In addition to exhibiting antitumor potential, antitumor drugs exhibit toxicity due to a poor pharmacokinetic profile. An enormous amount of research has been carried out and is still ongoing to obtain more targeted, potent, and safe drugs to
Abd-Rabou +39 more
core +1 more source
5-(carbamoylmethylene)-oxazolidin-2-ones as a promising class of heterocycles inducing apoptosis triggered by increased ROS levels and mitochondrial dysfunction in breast and cervical cancer [PDF]
, 2020 Oxazolidinones are antibiotics that inhibit protein synthesis by binding the 50S ribosomal subunit. Recently, numerous worldwide researches focused on their properties and possible involvement in cancer therapy have been conducted.
Armentano, B +10 more
core +2 more sources